Business Description
TheraCryf PLC
ISIN : GB00BSVYN304
Total Employee Number:
9Description
TheraCryf PLC is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of unmet medical need within central nervous system (CNS) disorders. The Group's main programme is a novel, benchmark orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol, and other substance use disorders. It also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy, and narcolepsy. The Group also has an oncology programme in glioblastoma with SFX-01. It operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.73 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 30.7 | |||||
3-Year EPS without NRI Growth Rate | 26.3 | |||||
3-Year FCF Growth Rate | 23.7 | |||||
3-Year Book Growth Rate | -55.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 6.62 | |||||
9-Day RSI | 20.88 | |||||
14-Day RSI | 31.87 | |||||
3-1 Month Momentum % | 23.08 | |||||
6-1 Month Momentum % | 14.29 | |||||
12-1 Month Momentum % | -5.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.29 | |||||
Quick Ratio | 2.29 | |||||
Cash Ratio | 1.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -97.9 | |||||
Shareholder Yield % | -92.01 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -44.85 | |||||
ROA % | -34.67 | |||||
ROIC % | -90.54 | |||||
3-Year ROIIC % | 31.51 | |||||
ROC (Joel Greenblatt) % | -783.19 | |||||
ROCE % | -49.92 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.08 | |||||
EV-to-EBIT | -0.5 | |||||
EV-to-EBITDA | -0.51 | |||||
EV-to-Forward-Revenue | 3.05 | |||||
EV-to-FCF | -0.66 | |||||
Earnings Yield (Greenblatt) % | -200 | |||||
FCF Yield % | -36.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TheraCryf PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | |||
| EPS (TTM) (£) | -0.002 | ||
| Beta | 2.7278 | ||
| 3-Year Sharpe Ratio | -0.53 | ||
| 3-Year Sortino Ratio | -0.83 | ||
| Volatility % | 29.1 | ||
| 14-Day RSI | 31.87 | ||
| 14-Day ATR (£) | 0.000102 | ||
| 20-Day SMA (£) | 0.00223 | ||
| 12-1 Month Momentum % | -5.88 | ||
| 52-Week Range (£) | 0.00175 - 0.003 | ||
| Shares Outstanding (Mil) | 2,148.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TheraCryf PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TheraCryf PLC Stock Events
| Event | Date | Price (£) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-12-03 11:00 | In 143 days | ||
| Second quarter earnings results for 2027 | 2026-12-03 | In 142 days | ||
| General meeting for 2026 | 2026-07-29 13:30 | In 16 days | ||
| Annual report for 2026 | 2026-07-22 | In 8 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-07-15 | In 1 day | ||
| Fourth quarter earnings results for 2026 | 2026-07-15 | In 1 day | ||
| Second quarter earnings conference call for 2026 | 2025-12-03 11:00 | 0.00 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2025-12-03 | 0.00 (+0.00%) | ||
| General meeting for 2025 | 2025-07-09 13:30 | 0.00 (+0.00%) | ||
| Annual report for 2025 | 2025-06-16 | 0.00 (-2.08%) |
Show
Entries
TheraCryf PLC Frequently Asked Questions
What is TheraCryf PLC(LSE:TCF)'s stock price today?
The current price of LSE:TCF is £0.00. The 52 week high of LSE:TCF is £0.00 and 52 week low is £0.00.
When is next earnings date of TheraCryf PLC(LSE:TCF)?
The next earnings date of TheraCryf PLC(LSE:TCF) is 2026-07-15 Est..
Does TheraCryf PLC(LSE:TCF) pay dividends? If so, how much?
TheraCryf PLC(LSE:TCF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on TheraCryf PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers